Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 4—April 2004

Research

Antigenic and Genetic Variability of Human Metapneumoviruses

Bernadette G. van den Hoogen*, Sander Herfst*, Leo Sprong*, Patricia A. Cane†, Eduardo Forleo-Neto‡, Rik L. de Swart*, Albert D.M.E. Osterhaus*, and Ron A.M. Fouchier*Comments to Author 
Author affiliations: *Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; †University of Birmingham Medical School, Birmingham, United Kingdom; ‡Vigi Virus, São Paulo, Brazil

Main Article

Table 2

Homologous and heterologous virus neutralizing antibody titers of serum samples obtained from ferrets infected with HMPV viruses belonging to different genetic sublineagesa,b

Experiment Virus used in virus neutralization TCID50/well Ferret 1 NL/1/00 [A1] Ferret 2 NL/1/99 [B1]
1
NL/1/00
12
1,024
32
NL/1/99
9
16
512
2
NL/1/00
30
1,024
8
NL/1/99
20
8
768
3
NL/1/00
40
768
24
NL/1/99
25
16
768
Ratio A–B


48–128

Ratio B–A 16–96

aVirus neutralizing antibody titers obtained in three independent experiments for serum samples collected 28 days postinfection from ferrets 1 and ferret 2 (infected with NL/1/00 and NL/1/99 respectively). TCID50, 50% tissue culture infectious dose; HMPV, human metapneumovirus.
bHomologous virus neutralization titers are bold. Values are average of duplicate measurements. Ratios are given as the homologous virus neutralization titers divided by the heterologous virus neutralization titers.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO